Dzmitry Skazau/iStock via Getty Images
Codexis (NASDAQ:CDXS) said it has finalized a sales agreement with Crosswalk Therapeutics for its gene therapy programs for Fabry and Pompe disease that were discontinued by partner Takeda (TAK) in April 2023.
Under the agreement, Codexis will be eligible to receive development and commercial milestone payments, along with a low-to-mid-single digit percentage royalty based on net sales. The company didn’t disclose financial details in its announcement of the finalized agreement.
Codexis noted that Crosswalk is led by former members of Takeda’s rare disease unit.